{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:47:24Z","timestamp":1787510844055,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10620-018-5007-6","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T20:54:13Z","timestamp":1522097653000},"page":"1878-1889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran"],"prefix":"10.1007","volume":"63","author":[{"given":"Jennifer M.","family":"Kolb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Friedman","family":"Flack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapti","family":"Chatterjee-Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars C.","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ilgenfritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Aisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"5007_CR1","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","volume":"129","author":"MW Sherwood","year":"2014","unstructured":"Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular. Circulation. 2014;129:1850\u20131859.","journal-title":"Circulation"},{"key":"5007_CR2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/0002-9149(67)90010-0","volume":"20","author":"LBR Michaels","year":"1967","unstructured":"Michaels LBR. Relapses of thromboembolic disease after discontinued anticoagulant therapy. A comparison of the incidence after abrupt and after gradual termination of treatment. Am J Cardiol. 1967;20:670\u2013673.","journal-title":"Am J Cardiol"},{"key":"5007_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0002-9343(89)80690-4","volume":"87","author":"CS Landefeld","year":"1989","unstructured":"Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989;87:153\u2013159.","journal-title":"Am J Med"},{"key":"5007_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"17","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;17:1139\u20131151.","journal-title":"N Engl J Med"},{"key":"5007_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cgh.2016.10.011","volume":"15","author":"KF Flack","year":"2017","unstructured":"Flack KF, Desai J, Kolb JM, et al. Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or dabigatran atrial fibrillation. Clin Gastroenterol Hepatol. 2017;15:682\u2013690.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5007_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u2013694.","journal-title":"J Thromb Haemost"},{"key":"5007_CR7","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMc1007378","volume":"363","author":"SJ Connolly","year":"2010","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin LC. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875\u20131876.","journal-title":"N Engl J Med"},{"key":"5007_CR8","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"31","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;31:2363\u20132372.","journal-title":"Circulation"},{"key":"5007_CR9","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","volume":"66","author":"MW Sherwood","year":"2015","unstructured":"Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015;66:2271\u20132281.","journal-title":"J Am Coll Cardiol"},{"key":"5007_CR10","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","volume":"63","author":"EM Hylek","year":"2014","unstructured":"Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin. J Am Coll Cardiol. 2014;63:2141\u20132147.","journal-title":"J Am Coll Cardiol"},{"key":"5007_CR11","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u20132104.","journal-title":"N Engl J Med"},{"key":"5007_CR12","doi-asserted-by":"crossref","unstructured":"Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015 Jan [cited 2016 Apr 30];350:h1857.","DOI":"10.1136\/bmj.h1857"},{"key":"5007_CR13","first-page":"S2","volume":"66","author":"CV Pollack","year":"2015","unstructured":"Pollack CV, Gruenenfelder F, Eikelboom J, et al. Initial experience with idarucizumab in dabigatran-treated patients presenting with acute gastrointestinal hemorrhage: interim results from the RE-VERSE AD study. Ann Emerg Med. 2015;66:S2\u2013S3.","journal-title":"Ann Emerg Med"},{"key":"5007_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/heartjnl-2012-301632","volume":"98","author":"R Casado Arroyo","year":"2012","unstructured":"Casado Arroyo R, Polo-Tomas M, Roncales MP, Scheiman J, Lanas A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 2012;98:718\u2013723.","journal-title":"Heart"},{"key":"5007_CR15","doi-asserted-by":"publisher","first-page":"e0151332","DOI":"10.1371\/journal.pone.0151332","volume":"11","author":"N Nagata","year":"2016","unstructured":"Nagata N, Niikura R, Yamada A, et al. Acute middle gastrointestinal bleeding risk associated with NSAIDs, antithrombotic drugs, and PPIs: a multicenter case-control study. PLoS One. 2016;11:e0151332.","journal-title":"PLoS One"},{"key":"5007_CR16","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1542-3565(15)00174-3","volume":"13","author":"\u00c1 Lanas","year":"2015","unstructured":"Lanas \u00c1, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13:e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5007_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433\u20131441.","journal-title":"Arch Intern Med"},{"key":"5007_CR18","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1053\/j.gastro.2015.03.052","volume":"149","author":"EW Chan","year":"2015","unstructured":"Chan EW, Lau WCY, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149:e3.","journal-title":"Gastroenterology"},{"key":"5007_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ajgsup.2016.2","volume":"3","author":"NS Abraham","year":"2016","unstructured":"Abraham NS. Prevention of gastrointestinal bleeding in patients receiving direct oral anticoagulants. Am J Gastroenterol Suppl. 2016;3:2\u201312.","journal-title":"Am J Gastroenterol Suppl"},{"key":"5007_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386\u2013399.","journal-title":"Drug Metab Dispos"},{"key":"5007_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14740338.2017.1325870","volume":"16","author":"A Lanas-Gimeno","year":"2017","unstructured":"Lanas-Gimeno A, Lanas A. Expert opinion on drug safety risk of gastrointestinal bleeding during anticoagulant treatment. Exp Opin Drug Saf. 2017;16:673\u2013685.","journal-title":"Exp Opin Drug Saf"},{"key":"5007_CR22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/ajg.2015.246","volume":"110","author":"LB Gerson","year":"2015","unstructured":"Gerson LB, Fidler JL, Cave DR, Leighton JA. ACG clinical guideline: diagnosis and management of small bowel bleeding. Am J Gastroenterol. 2015;110:1265\u20131287.","journal-title":"Am J Gastroenterol"},{"key":"5007_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.dld.2012.10.004","volume":"45","author":"M Manno","year":"2013","unstructured":"Manno M, Riccioni ME, Cannizzaro R, Andreoli A, Marmo R, Pennazio M. Diagnostic and therapeutic yield of single balloon enteroscopy in patients with suspected small-bowel disease: results of the Italian multicentre study. Dig Liver Dis. 2013;45:211\u2013215.","journal-title":"Dig Liver Dis"},{"key":"5007_CR24","first-page":"141","volume":"19","author":"ST Turenhout van","year":"2010","unstructured":"van Turenhout ST, Jacobs MA, van Weyenberg SJ, et al. Diagnostic yield of capsule endoscopy in a tertiary hospital in patients with obscure gastrointestinal bleeding. J Gastrointestin Liver Dis. 2010;19:141\u2013145.","journal-title":"J Gastrointestin Liver Dis"},{"key":"5007_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1443-1661.2011.01228.x","volume":"24","author":"SJB Weyenberg Van","year":"2012","unstructured":"Van Weyenberg SJB, Van Turenhout ST, Jacobs MAJM, Bouma G, Mulder CJJ. Video capsule endoscopy for previous overt obscure gastrointestinal bleeding in patients using anti-thrombotic drugs. Dig Endosc. 2012;24:247\u2013254.","journal-title":"Dig Endosc"},{"key":"5007_CR26","doi-asserted-by":"publisher","first-page":"709217","DOI":"10.1155\/2014\/709217","volume":"2014","author":"P Boal Carvalho","year":"2014","unstructured":"Boal Carvalho P, Rosa B, Moreira MJ, Cotter J. New evidence on the impact of antithrombotics in patients submitted to small bowel capsule endoscopy for the evaluation of obscure gastrointestinal bleeding. Gastroenterol Res Pract. 2014;2014:709217.","journal-title":"Gastroenterol Res Pract"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5007-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T09:18:01Z","timestamp":1570958281000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5007-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["5007"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5007-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"11 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jennifer M. Kolb, Kathryn Friedman Flack, Prapti Chatterjee-Murphy, and John Ilgenfritz have no conflicts of interest to disclose. Jay Desai reports non-financial support from Boehringer Ingelheim, and he has participated in advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, and Daiichi Sankyo. Lars C. Wallentin has received grant support\/honoraria\/consulting fees from Boehringer Ingelheim, Regado Biosciences, Athera Biosciences, AstraZeneca, GlaxoSmithKline, Eli Lilly, Schering-Plough, and Bristol-Myers Squibb. Michael Ezekowitz has served as a consultant for AstraZeneca, Eisai, Pozen Inc., Boehringer Ingelheim, ARYx Therapeutics, Pfizer, Sanofi, Bristol-Myers Squibb, Portola, Daiichi Sankyo, Medtronic, Merck, Johnson & Johnson, Gilead, Janssen Scientific Affairs, and Armetheon. He has received research grant support from Boehringer Ingelheim, Bayer, Daiichi Sankyo, Pfizer, and Bristol-Myers Squibb. Stuart Connolly has received grant support\/honoraria\/consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, and Portola. Paul Reilly is a full-time employee of Boehringer Ingelheim. Martina Brueckmann is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. James Aisenberg reports he has participated in advisory boards and consulting for Boehringer Ingelheim and Portola.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}